Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array BioPharma Inc. today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015.

3 Aug 2015

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has engaged the services of a specialty specimen management clinical research organization, Global Specimen Solutions, Inc., to support initial U.S. market entry of its NuQ colorectal cancer tests.

28 Jul 2015

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.

28 Jul 2015

Case Western cancer researchers develop algorithm to detect DNA copy-number alterations in tumors

An algorithm dubbed ENVE could be the Google for genetic aberrations — and it comes from Case Western Reserve.

24 Jul 2015

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

UCLA scientists have discovered a groundbreaking experimental therapy that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhibitor able to block an RNA molecule (microRNA-214) involved in the transmission of genetic information.

24 Jul 2015

Check-Cap provides corporate update, reports financial results for second quarter 2015

Check-Cap Ltd., a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced financial results for the second quarter, ended June 30, 2015.

21 Jul 2015

State healthcare regulations linked to late-stage cancer diagnoses

States' regulations of health insurance and practitioners significantly influence when patients receive colorectal or breast cancer diagnoses, especially among people younger than the Medicare-eligible age of 65, according to a new study by researchers at Georgia State University's School of Public Health and the University of North Carolina at Chapel Hill.

21 Jul 2015

MD Anderson researchers find high prevalence of hereditary CRC among people diagnosed before the age of 35

Hereditary colorectal cancers, caused by inherited gene mutations, are relatively rare for most patients. However, researchers at The University of Texas MD Anderson Cancer Center have discovered a particularly high prevalence of hereditary cancers among those diagnosed with the disease before the age of 35. They suggest that these patients should undergo genetic counseling to determine if their families may be at an elevated risk.

21 Jul 2015

NeoGenomics announces launch of new germline cancer predisposition testing services

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of a new line of germline cancer predisposition testing services. The new tests include comprehensive testing for BRCA1 and BRCA2 encompassing an analysis of all exons and adjacent intronic regions.

20 Jul 2015

Noninvasive prenatal testing clue to maternal malignancy

A preliminary study lends support to the hypothesis that a false-positive noninvasive prenatal test finding could be due to the presence of an occult maternal cancer.

16 Jul 2015

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

US-Australian drug discovery company, Novogen Limited, today announced that it has received notification from the U.S. Food and Drug Administration that its chemotherapy candidate drug, Anisina, has been granted Orphan Drug Designation for neuroblastoma.

16 Jul 2015

Noninvasive prenatal screening could detect maternal cancer

A study published today in the Journal of the American Medical Association shows that genetic test results, as revealed by non-invasive prenatal testing for fetal chromosome abnormalities, may detect underlying conditions in the mother, including cancer.

15 Jul 2015

Colorectal cancer patients diagnosed during screening colonoscopy survive longer

Patients whose colorectal cancer (CRC) is detected during a screening colonoscopy are likely to survive longer than those who wait until they have symptoms before having the test, according to a study in the July issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy.

14 Jul 2015

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

US-Australian drug discovery company, Novogen Limited, today announced details of an in vivo proof of concept study that demonstrates their lead anti-tropomyosin drug candidate, Anisina, has the potential to improve the effectiveness of chemotherapy in children and reduce life-long side-effects.

14 Jul 2015

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors.

8 Jul 2015

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

The phase IIIb CONSIGN study has confirmed the benefit of regorafenib in patients with previously treated metastatic colorectal cancer (mCRC), researchers announced at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

3 Jul 2015

NDSU researcher awarded $1.35 million research grant to develop targeted treatment for colorectal cancer

A researcher at North Dakota State University, Fargo, is receiving a four-year $1.35 million research project grant from the National Cancer Institute of the National Institutes of Health to develop a targeted treatment for colorectal cancer.

2 Jul 2015

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, antiemetics expert and ESMO spokesperson Fausto Roila said, putting into perspective the results of a Japanese study presented today at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona.

2 Jul 2015

Low BMI linked to poorer survival in advanced colorectal cancer

Although being overweight with a high body-mass index (BMI) has long been associated with a higher risk for colorectal cancer, thinner patients might not fare as well after treatment for advanced cancer, according to a new study from Duke Medicine.

2 Jul 2015

IBI scientists make progress in identifying new biomarkers for preventing colorectal cancer

Scientists from the Instituto de Investigación Biomédica [Institute of Biomedical Research], in Galicia (Spain), have made progress in the identification of new biomarkers for improving prevention of colorectal cancer.

1 Jul 2015

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Array Biopharma reports strong fourth quarter and full year 2015 financial results

VolitionRx selects Global Specimen Solutions to support U.S. market entry of NuQ colorectal cancer tests

Research brief describes enrollment of first patient with TRK fusion cancer in LOXO-101 Phase 1 trial

Case Western cancer researchers develop algorithm to detect DNA copy-number alterations in tumors

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

Check-Cap provides corporate update, reports financial results for second quarter 2015

State healthcare regulations linked to late-stage cancer diagnoses

MD Anderson researchers find high prevalence of hereditary CRC among people diagnosed before the age of 35

NeoGenomics announces launch of new germline cancer predisposition testing services

Noninvasive prenatal testing clue to maternal malignancy

Novogen's Anisina granted FDA Orphan Drug Designation for neuroblastoma

Noninvasive prenatal screening could detect maternal cancer

Colorectal cancer patients diagnosed during screening colonoscopy survive longer

Study shows that Anisina has potential to improve effectiveness of chemotherapy in children with cancer

Ludwig, CRI launch clinical trials to evaluate immunotherapies for treatment of GBM and solid tumors

Phase IIIb CONSIGN study confirms benefit of regorafenib in patients with pre-treated mCRC

NDSU researcher awarded $1.35 million research grant to develop targeted treatment for colorectal cancer

SENRI Trial: NK1 antagonists may prevent emesis in patients treated with oxaliplatin-based chemotherapy

Low BMI linked to poorer survival in advanced colorectal cancer

IBI scientists make progress in identifying new biomarkers for preventing colorectal cancer

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in